Characteristics of 779 patients diagnosed with CML in Sweden in 2002-2010
| . | Men, n = 425 . | Women, n = 354 . | P* . | Patients living in university hospital catchment areas, n = 285 . | Patients living in other areas, n = 494 . | P* . | Total, N = 779 . |
|---|---|---|---|---|---|---|---|
| Sex, no. (%) | |||||||
| Men | 157 (55.1) | 268 (54.3) | 425 (54.6) | ||||
| Women | 128 (44.9) | 226 (45.7) | .080 | 354 (45.4) | |||
| Age at diagnosis | |||||||
| Median (IQR) | 60 (44-71) | 59 (49-71) | .567 | 60 (46-71) | 59 (46-71) | .902 | 60 (46-71) |
| Age at diagnosis, no. (%) | |||||||
| <50 | 140 (32.9) | 96 (27.1) | 91 (31.9) | 145 (29.4) | 236 (30.3) | ||
| 50-59 | 70 (16.5) | 83 (23.4) | 50 (17.5) | 103 (20.9) | 153 (19.6) | ||
| 60-69 | 90 (21.2) | 74 (20.9) | 60 (21.1) | 104 (21.1) | 164 (21.1) | ||
| 70-79 | 75 (17.6) | 56 (15.8) | 52 (18.2) | 79 (16.0) | 131 (16.8) | ||
| 80+ | 70 (11.8) | 45 (12.7) | .113 | 32 (11.2) | 63 (12.8) | .682 | 95 (12.2) |
| Basis of diagnosis, no. (%) | |||||||
| Karyotyping | 109 (25.6) | 118 (33.3) | 94 (33.0) | 133 (26.9) | 227 (29.1) | ||
| Karyotyping + FISH | 56 (13.2) | 39 (11.0) | 41 (14.4) | 54 (10.9) | 95 (12.2) | ||
| Karyotyping + RT-PCR | 68 (16.0) | 76 (21.5) | 43 (15.1) | 101 (20.4) | 144 (18.5) | ||
| Karyotyping + FISH + RT-PCR | 93 (21.9) | 65 (18.4) | 55 (19.3) | 103 (20.9) | 158 (20.3) | ||
| FISH | 28 (6.6) | 24 (6.8) | 20 (7.0) | 32 (6.5) | 52 (6.7) | ||
| FISH + RT-PCR | 19 (4.5) | 7 (2.0) | 10 (3.5) | 16 (3.2) | 26 (3.3) | ||
| RT-PCR | 35 (8.2) | 18 (5.1) | 15 (5.3) | 38 (7.7) | 53 (6.8) | ||
| Missing | 17 (4.0) | 7 (2.0) | .012 | 7 (2.5) | 17 (3.4) | .230 | 24 (3.1) |
| WHO performance status, no. (%) | |||||||
| WHO 0 | 261 (61.4) | 185 (52.3) | 168 (58.9) | 278 (56.3) | 446 (57.3) | ||
| WHO 1 | 115 (27.1) | 111 (31.4) | 79 (27.7) | 147 (29.8) | 226 (29.0) | ||
| WHO 2-4 | 36 (8.5) | 43 (12.1) | 29 (10.2) | 50 (10.1) | 79 (10.1) | ||
| Missing | 13 (3.1) | 15 (4.2) | .061 | 9 (3.2) | 19 (3.8) | .868 | 28 (3.6) |
| Phase at diagnosis, no. (%) | |||||||
| CP | 386 (90.8) | 331 (93.5) | 264 (92.6) | 453 (91.7) | 717 (92.0) | ||
| AP | 21 (4.9) | 12 (3.4) | 12 (4.2) | 21 (4.3) | 33 (4.2) | ||
| Blast crisis | 12 (2.8) | 7 (2.0) | 7 (2.5) | 12 (2.4) | 19 (2.4) | ||
| Missing | 6 (1.4) | 4 (1.1) | .600 | 2 (0.7) | 8 (1.6) | .801 | 10 (1.3) |
| Spleen size (cm) | |||||||
| Median (IQR) | 0 (0-6) | 0 (0-5) | .170 | 0 (0.6) | 0 (0-6) | .201 | 0 (0-6) |
| Missing, no. (%) | 18 (4.2) | 10 (2.8) | 5 (1.8) | 23 (4.7) | 28 (3.6) | ||
| Hemoglobin (g/L) | |||||||
| Median (IQR) | 114 (101-130) | 112 (96-125) | .016 | 112.5 (100-128) | 114 (99-128) | .992 | 113 (99-128) |
| Missing, no. (%) | 0 (0.0) | 4 (1.1) | 1 (0.4) | 3 (0.6) | 4 (0.5) | ||
| Platelet count (109/L) | |||||||
| Median (IQR) | 391 (236-592) | 512 (342-833) | <.001 | 439.5 (284-693) | 431 (265-715) | .778 | 433 (274-704) |
| Missing, no. (%) | 0 (0.0) | 3 (0.8) | 1 (0.4) | 2 (0.4) | 3 (0.4) | ||
| White blood cell count (109/L) | |||||||
| Median (IQR) | 119 (52.3-110.2) | 106 (44.9-206) | .298 | 103.5 (49-194) | 118 (52-212.5) | .203 | 112 (50-209) |
| Missing, no. (%) | 1 (0.2) | 3 | 1 (0.4) | 3 (0.6) | 4 (0.5) | ||
| Percentage blast cells in blood | |||||||
| Median (IQR) | 1 (0-3.5) | 1 (0-3.4) | .682 | 1 (0-3) | 1 (0-3.5) | .228 | 1 (0-3.4) |
| Missing, no. (%) | 6 (1.4) | 5 (1.4) | 2 (0.7) | 9 (1.8) | 11 (1.4) | ||
| Percentage eosinophils in blood | |||||||
| Median (IQR) | 2 (1-4) | 2 (1-4) | .706 | 2.5 (1-4.5) | 2 (1-4) | .090 | 2 (1-4) |
| Missing, no. (%) | 15 (3.5) | 9 (2.5) | 11 (3.9) | 13 (2.6) | 24 (3.1) | ||
| Percentage basophils in blood | |||||||
| Median (IQR) | 3.5 (1.9-6.9) | 4 (2-7) | .088 | 3.9 (2-7) | 3.7 (2-6.9) | .905 | 3.8 (2-6.9) |
| Missing, no. (%) | 15 (3.5) | 8 (2.3) | 10 (3.5) | 13 (2.6) | 23 (3.0) | ||
| Percentage blast cells in bone marrow | |||||||
| Median (IQR) | 2 (1-4) | 2 (1-4) | .300 | 2 (1-4) | 2 (1-4) | .619 | 2 (1-4) |
| Missing, no. (%) | 47 (11.1) | 40 (11.3) | 30 (10.5) | 57 (11.5) | 87 (11.2) |
| . | Men, n = 425 . | Women, n = 354 . | P* . | Patients living in university hospital catchment areas, n = 285 . | Patients living in other areas, n = 494 . | P* . | Total, N = 779 . |
|---|---|---|---|---|---|---|---|
| Sex, no. (%) | |||||||
| Men | 157 (55.1) | 268 (54.3) | 425 (54.6) | ||||
| Women | 128 (44.9) | 226 (45.7) | .080 | 354 (45.4) | |||
| Age at diagnosis | |||||||
| Median (IQR) | 60 (44-71) | 59 (49-71) | .567 | 60 (46-71) | 59 (46-71) | .902 | 60 (46-71) |
| Age at diagnosis, no. (%) | |||||||
| <50 | 140 (32.9) | 96 (27.1) | 91 (31.9) | 145 (29.4) | 236 (30.3) | ||
| 50-59 | 70 (16.5) | 83 (23.4) | 50 (17.5) | 103 (20.9) | 153 (19.6) | ||
| 60-69 | 90 (21.2) | 74 (20.9) | 60 (21.1) | 104 (21.1) | 164 (21.1) | ||
| 70-79 | 75 (17.6) | 56 (15.8) | 52 (18.2) | 79 (16.0) | 131 (16.8) | ||
| 80+ | 70 (11.8) | 45 (12.7) | .113 | 32 (11.2) | 63 (12.8) | .682 | 95 (12.2) |
| Basis of diagnosis, no. (%) | |||||||
| Karyotyping | 109 (25.6) | 118 (33.3) | 94 (33.0) | 133 (26.9) | 227 (29.1) | ||
| Karyotyping + FISH | 56 (13.2) | 39 (11.0) | 41 (14.4) | 54 (10.9) | 95 (12.2) | ||
| Karyotyping + RT-PCR | 68 (16.0) | 76 (21.5) | 43 (15.1) | 101 (20.4) | 144 (18.5) | ||
| Karyotyping + FISH + RT-PCR | 93 (21.9) | 65 (18.4) | 55 (19.3) | 103 (20.9) | 158 (20.3) | ||
| FISH | 28 (6.6) | 24 (6.8) | 20 (7.0) | 32 (6.5) | 52 (6.7) | ||
| FISH + RT-PCR | 19 (4.5) | 7 (2.0) | 10 (3.5) | 16 (3.2) | 26 (3.3) | ||
| RT-PCR | 35 (8.2) | 18 (5.1) | 15 (5.3) | 38 (7.7) | 53 (6.8) | ||
| Missing | 17 (4.0) | 7 (2.0) | .012 | 7 (2.5) | 17 (3.4) | .230 | 24 (3.1) |
| WHO performance status, no. (%) | |||||||
| WHO 0 | 261 (61.4) | 185 (52.3) | 168 (58.9) | 278 (56.3) | 446 (57.3) | ||
| WHO 1 | 115 (27.1) | 111 (31.4) | 79 (27.7) | 147 (29.8) | 226 (29.0) | ||
| WHO 2-4 | 36 (8.5) | 43 (12.1) | 29 (10.2) | 50 (10.1) | 79 (10.1) | ||
| Missing | 13 (3.1) | 15 (4.2) | .061 | 9 (3.2) | 19 (3.8) | .868 | 28 (3.6) |
| Phase at diagnosis, no. (%) | |||||||
| CP | 386 (90.8) | 331 (93.5) | 264 (92.6) | 453 (91.7) | 717 (92.0) | ||
| AP | 21 (4.9) | 12 (3.4) | 12 (4.2) | 21 (4.3) | 33 (4.2) | ||
| Blast crisis | 12 (2.8) | 7 (2.0) | 7 (2.5) | 12 (2.4) | 19 (2.4) | ||
| Missing | 6 (1.4) | 4 (1.1) | .600 | 2 (0.7) | 8 (1.6) | .801 | 10 (1.3) |
| Spleen size (cm) | |||||||
| Median (IQR) | 0 (0-6) | 0 (0-5) | .170 | 0 (0.6) | 0 (0-6) | .201 | 0 (0-6) |
| Missing, no. (%) | 18 (4.2) | 10 (2.8) | 5 (1.8) | 23 (4.7) | 28 (3.6) | ||
| Hemoglobin (g/L) | |||||||
| Median (IQR) | 114 (101-130) | 112 (96-125) | .016 | 112.5 (100-128) | 114 (99-128) | .992 | 113 (99-128) |
| Missing, no. (%) | 0 (0.0) | 4 (1.1) | 1 (0.4) | 3 (0.6) | 4 (0.5) | ||
| Platelet count (109/L) | |||||||
| Median (IQR) | 391 (236-592) | 512 (342-833) | <.001 | 439.5 (284-693) | 431 (265-715) | .778 | 433 (274-704) |
| Missing, no. (%) | 0 (0.0) | 3 (0.8) | 1 (0.4) | 2 (0.4) | 3 (0.4) | ||
| White blood cell count (109/L) | |||||||
| Median (IQR) | 119 (52.3-110.2) | 106 (44.9-206) | .298 | 103.5 (49-194) | 118 (52-212.5) | .203 | 112 (50-209) |
| Missing, no. (%) | 1 (0.2) | 3 | 1 (0.4) | 3 (0.6) | 4 (0.5) | ||
| Percentage blast cells in blood | |||||||
| Median (IQR) | 1 (0-3.5) | 1 (0-3.4) | .682 | 1 (0-3) | 1 (0-3.5) | .228 | 1 (0-3.4) |
| Missing, no. (%) | 6 (1.4) | 5 (1.4) | 2 (0.7) | 9 (1.8) | 11 (1.4) | ||
| Percentage eosinophils in blood | |||||||
| Median (IQR) | 2 (1-4) | 2 (1-4) | .706 | 2.5 (1-4.5) | 2 (1-4) | .090 | 2 (1-4) |
| Missing, no. (%) | 15 (3.5) | 9 (2.5) | 11 (3.9) | 13 (2.6) | 24 (3.1) | ||
| Percentage basophils in blood | |||||||
| Median (IQR) | 3.5 (1.9-6.9) | 4 (2-7) | .088 | 3.9 (2-7) | 3.7 (2-6.9) | .905 | 3.8 (2-6.9) |
| Missing, no. (%) | 15 (3.5) | 8 (2.3) | 10 (3.5) | 13 (2.6) | 23 (3.0) | ||
| Percentage blast cells in bone marrow | |||||||
| Median (IQR) | 2 (1-4) | 2 (1-4) | .300 | 2 (1-4) | 2 (1-4) | .619 | 2 (1-4) |
| Missing, no. (%) | 47 (11.1) | 40 (11.3) | 30 (10.5) | 57 (11.5) | 87 (11.2) |
IQR, interquartile range; WHO, World Health Organization.
P value for the null hypothesis of no difference between the sexes or the patients’ area of residence.